Pulse Biosciences, which is developing pulsed electric field technology to treat solid tumors, last week filed for an initial public offering worth $20 million.
Burlingame, Calif.-based Pulse said it plans to float 5 million shares at $4 apiece, for a fully diluted valuation of $51 million.
Burlingame, Calif.-based Pulse said it plans to float 5 million shares at $4 apiece, for a fully diluted valuation of $51 million.
